跳至主要内容
临床试验/NCT01360073
NCT01360073已完成不适用

Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death - Nested Case Control Analyses in a Cohort of Patients With Acute Serious Coronary Heart Disease

AstraZeneca1 个研究点 分布在 1 个国家目标入组 42,542 人开始时间: 2011年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
42,542
试验地点
1
主要终点
Nonfatal MI or coronary death

研究概览

简要总结

The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and proton pump inhibitors (PPIs) in patients with serious coronary heart disease using two UK primary care databases.

详细描述

Number of Anticipated Subjects: In case-control analysis: 10.000-15.000 participants

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
50 Years 至 84 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • As above ( study population description).
  • All individuals aged 50-84 years with at least one year of enrolment with the primary care physician (PCP) and a computerized prescription history of at least one year before the start of the study.

排除标准

  • Recorded diagnosis of cancer prior to study start.
  • Patients aged ≥ 70 years with a follow-up longer than one year if having fewer than two recorded consultations with a primary care physician (PCP) during their entire follow-up (proxy for incomplete and invalid data recording

结局指标

主要结局

Nonfatal MI or coronary death

时间窗: Up to eight years from entry into study cohort

次要结局

未报告次要终点

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验